miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we ident...

Full description

Bibliographic Details
Main Authors: Besskaya, V. (Author), Bi, G. (Author), Bian, Y. (Author), Chen, Z. (Author), Huang, Y. (Author), Jin, X. (Author), Liang, J. (Author), Lu, T. (Author), Tan, L. (Author), Wang, Q. (Author), Zhan, C. (Author), Zhang, H. (Author), Zhao, M. (Author), Zheng, Y. (Author)
Format: Article
Language:English
Published: Cell Press 2022
Subjects:
cell-cycle arrest
chemoresistance
cisplatin
CRISPR-Cas9
ferroptosis
homology-directed repair
lncRNA
miRNA
MT: Non-coding RNAs
pemetrexed
RNA-seq
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items